216 related articles for article (PubMed ID: 34998918)
1. Surface glycan targeting for cancer nano-immunotherapy.
Choi Y; Kim J; Chae J; Hong J; Park J; Jeong E; Kim H; Tanaka M; Okochi M; Choi J
J Control Release; 2022 Feb; 342():321-336. PubMed ID: 34998918
[TBL] [Abstract][Full Text] [Related]
2. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery.
Jin Q; Liu Z; Chen Q
J Control Release; 2021 Jan; 329():882-893. PubMed ID: 33053396
[TBL] [Abstract][Full Text] [Related]
3. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
4. Delivering safer immunotherapies for cancer.
Milling L; Zhang Y; Irvine DJ
Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
[TBL] [Abstract][Full Text] [Related]
5. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.
Farhadi SA; Hudalla GA
Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902
[TBL] [Abstract][Full Text] [Related]
6. Using the glycan toolbox for pathogenic interventions and glycan immunotherapy.
Li RE; van Vliet SJ; van Kooyk Y
Curr Opin Biotechnol; 2018 Jun; 51():24-31. PubMed ID: 29175707
[TBL] [Abstract][Full Text] [Related]
7. Emerging glyco-based strategies to steer immune responses.
Anderluh M; Berti F; Bzducha-Wróbel A; Chiodo F; Colombo C; Compostella F; Durlik K; Ferhati X; Holmdahl R; Jovanovic D; Kaca W; Lay L; Marinovic-Cincovic M; Marradi M; Ozil M; Polito L; Reina-Martin JJ; Reis CA; Sackstein R; Silipo A; Švajger U; Vaněk O; Yamamoto F; Richichi B; van Vliet SJ
FEBS J; 2021 Aug; 288(16):4746-4772. PubMed ID: 33752265
[TBL] [Abstract][Full Text] [Related]
8. Tumour associated glycans: A route to boost immunotherapy?
Scott E; Elliott DJ; Munkley J
Clin Chim Acta; 2020 Mar; 502():167-173. PubMed ID: 31870793
[TBL] [Abstract][Full Text] [Related]
9. Targeting the innate immune system with nanoparticles for cancer immunotherapy.
Li K; Zhang Z; Mei Y; Li M; Yang Q; Wu Q; Yang H; He L; Liu S
J Mater Chem B; 2022 Mar; 10(11):1709-1733. PubMed ID: 35179545
[TBL] [Abstract][Full Text] [Related]
10. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
11. Delivery technologies for cancer immunotherapy.
Riley RS; June CH; Langer R; Mitchell MJ
Nat Rev Drug Discov; 2019 Mar; 18(3):175-196. PubMed ID: 30622344
[TBL] [Abstract][Full Text] [Related]
12. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
13. Various Tastes of Sugar: The Potential of Glycosylation in Targeting and Modulating Human Immunity via C-Type Lectin Receptors.
Busold S; Nagy NA; Tas SW; van Ree R; de Jong EC; Geijtenbeek TBH
Front Immunol; 2020; 11():134. PubMed ID: 32117281
[TBL] [Abstract][Full Text] [Related]
14. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses.
Chen Q; Chen M; Liu Z
Chem Soc Rev; 2019 Nov; 48(22):5506-5526. PubMed ID: 31589233
[TBL] [Abstract][Full Text] [Related]
15. Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.
Shah SA; Oakes RS; Jewell CM
Adv Drug Deliv Rev; 2024 Jun; 209():115315. PubMed ID: 38670230
[TBL] [Abstract][Full Text] [Related]
16. Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression.
Silva MC; Fernandes Â; Oliveira M; Resende C; Correia A; de-Freitas-Junior JC; Lavelle A; Andrade-da-Costa J; Leander M; Xavier-Ferreira H; Bessa J; Pereira C; Henrique RM; Carneiro F; Dinis-Ribeiro M; Marcos-Pinto R; Lima M; Lepenies B; Sokol H; Machado JC; Vilanova M; Pinho SS
Cancer Immunol Res; 2020 Nov; 8(11):1407-1425. PubMed ID: 32933968
[TBL] [Abstract][Full Text] [Related]
17. Nano-immunotherapy: Overcoming tumour immune evasion.
Guevara ML; Persano F; Persano S
Semin Cancer Biol; 2021 Feb; 69():238-248. PubMed ID: 31883449
[TBL] [Abstract][Full Text] [Related]
18. Advances in herbal polysaccharides-based nano-drug delivery systems for cancer immunotherapy.
Han MM; Fan YK; Zhang Y; Dong ZQ
J Drug Target; 2024 Dec; 32(3):311-324. PubMed ID: 38269853
[TBL] [Abstract][Full Text] [Related]
19. Polysaccharide-based nanomedicines for cancer immunotherapy: A review.
Zeng Y; Xiang Y; Sheng R; Tomás H; Rodrigues J; Gu Z; Zhang H; Gong Q; Luo K
Bioact Mater; 2021 Oct; 6(10):3358-3382. PubMed ID: 33817416
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.
Fan Y; Moon JJ
Vaccines (Basel); 2015 Aug; 3(3):662-85. PubMed ID: 26350600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
